HLB’s precision cancer drug Rivoceranib has demonstrated the world’s longest median overall survival, or mOS, in phase 3 clinical trials of liver cancer, the South Korean biopharmaceutical company said Thursday. 

Please refer to the following website for further details:      

HLB’s anticancer drug candidate shows world’s longest survival duration against liver cancer (koreaherald.com)